Written and fact-checked by the After 50 Strong Editorial Team. Last updated: . About our editorial process

Benfotiamine for neuropathy: the B1 form that actually gets absorbed

Benfotiamine is a fat-soluble form of vitamin B1 that German doctors have prescribed for diabetic nerve problems since the 1990s. The absorption advantage over regular B1 is proven science. What the trials say about actual nerve relief is a more complicated story, with a clear pattern: short trials help, long trials disappoint. Here is the full record, doses included.

  • Absorption edge: roughly 11 times more thiamine reaches the bloodstream than regular B1.
  • Short trials: BEDIP (3 weeks) and BENDIP (6 weeks) found modest symptom relief.
  • Long trials: BOND (12 months) and Fraser (24 months) found no objective nerve benefit.
  • Best dose: 300 to 600 mg daily. The 600 mg arm worked better in BENDIP.
Senior woman holding a vitamin bottle and reading the supplement label at a kitchen table

Why regular vitamin B1 hits a ceiling

Your gut absorbs ordinary thiamine through an active transport system that saturates quickly. Once you pass roughly 8 to 15 mg per day, extra thiamine mostly passes through unused. Benfotiamine is built differently: its fat-soluble structure crosses the intestinal wall by passive diffusion, bypassing that ceiling entirely.

The difference is not small. In a pharmacokinetic study comparing equal oral doses, benfotiamine produced about 11 times more thiamine in the bloodstream and roughly double the active thiamine diphosphate inside red blood cells compared with standard thiamine hydrochloride. This is the rare supplement claim that is fully verified: the form genuinely absorbs better.

What the nerve trials actually found

BEDIP, 2005: the encouraging pilot

The BEDIP pilot trial gave 40 diabetic patients either 400 mg of benfotiamine daily or a placebo for three weeks. The neuropathy score, covering pain, sensation, reflexes, and coordination, improved significantly in the benfotiamine group (p = 0.0287), with the strongest effect on pain (p = 0.0414). No side effects were reported.

BENDIP, 2008: the bigger trial with an asterisk

BENDIP was a phase III trial with 165 patients comparing 300 mg and 600 mg of benfotiamine daily against placebo for six weeks. The primary symptom score improved significantly in the per-protocol analysis (p = 0.033), which counts only patients who followed the protocol exactly. In the stricter intention-to-treat analysis, which counts everyone, the result narrowly missed significance at p = 0.055. The Total Symptom Score showed no significant difference. Two details favored benfotiamine: the 600 mg dose outperformed 300 mg, and the effect grew between week three and week six.

BOND, 2026: the long trial that found nothing

The most recent and rigorous trial is the one marketing pages skip. The BOND study, published in January 2026 in BMJ Open Diabetes Research and Care, gave type 2 diabetes patients 600 mg of benfotiamine daily for a full year. The primary outcome was an objective one: the length of nerve fibers measured in the cornea, a validated window into nerve health. Benfotiamine moved nothing. Secondary nerve function measures, symptom scores, and quality of life all matched placebo. An earlier 24-month trial in type 1 diabetes, using 300 mg daily, also found no effect on nerve function.

The pattern across the record is consistent: short trials show symptom relief, long trials show no change in the nerves themselves. Relief without repair.

The mechanism: why scientists keep studying it

Benfotiamine activates an enzyme called transketolase, which diverts excess glucose away from three biochemical pathways that damage blood vessels and nerves in diabetes. A landmark 2003 Nature Medicine paper showed benfotiamine blocked all three pathways and prevented diabetic retinal damage in animals. That mechanism is real and elegant. It is also the reason trial results disappoint: a mechanism proven in cells and rodents does not guarantee a clinical effect in people, and so far the long human trials have not delivered one.

Doses: what the studies used

TrialDaily doseDurationResult
BEDIP (2005)400 mg3 weeksSymptom scores improved, strongest for pain
BENDIP (2008)300 mg vs 600 mg6 weeks600 mg arm better; significant only in per-protocol analysis
BOND (2026)600 mg12 monthsNo effect on any nerve measure
Fraser (type 1 diabetes)300 mg24 monthsNo effect on nerve function

If you try benfotiamine, the trial-supported range is 300 to 600 mg daily. Starting at 300 mg for the first month, then moving to 600 mg, mirrors the stronger BENDIP arm while letting you check tolerance.

How long to give it

BEDIP detected improvement at three weeks. BENDIP showed the effect growing through week six. A fair personal trial is eight to twelve weeks at a trial-level dose, with your tingling and burning rated weekly on a 0-to-10 scale. The BOND results carry a hard lesson here: if the number has not moved by week twelve, waiting longer is not supported by evidence.

Do not self-treat undiagnosed tingling. Benfotiamine only makes sense after you know why your feet tingle. Diabetes, prediabetes, B12 deficiency, thyroid disease, and spinal problems all cause identical symptoms and need different treatment. Ask your doctor for a glucose or A1C check and a B12 level before spending on any nerve supplement. Our B12 and nerve damage guide explains the most commonly missed cause.

Safety notes

Benfotiamine was well tolerated in every trial, including the 12-month BOND study. Reported side effects are mild: occasional stomach upset, headache, and rare skin reactions. There are no known serious drug interactions, though anyone using insulin or sulfonylurea drugs should monitor blood sugar when adding any nerve-support supplement, since better glucose handling can shift your numbers.

How it compares to alpha-lipoic acid

The two ingredients share a target, diabetic neuropathy, but different evidence shapes. Alpha-lipoic acid has larger and longer trials, including a four-year study that slowed measurable nerve decline, while benfotiamine has the better absorption story and the cleaner safety record. European practice has combined B vitamins with alpha-lipoic acid for decades. Details are in our alpha-lipoic acid guide. For the full ingredient map, visit the Nerve Health hub.

The bottom line

Benfotiamine solves a real problem: getting meaningful amounts of B1 into your tissues. For diabetic tingling and burning, the short trials justify an eight-to-twelve-week personal trial at 300 to 600 mg daily. Just hold the honest expectation: symptom relief is plausible, nerve regeneration is unproven, and the newest year-long trial found no objective benefit at all.

Frequently Asked Questions

Does benfotiamine really work for neuropathy?

The evidence is mixed, and it splits by trial length. Short trials found modest symptom relief: the 3-week BEDIP pilot improved neuropathy scores significantly, and the 6-week BENDIP trial found a significant benefit in its per-protocol analysis while narrowly missing it in the stricter analysis. The long trials are negative: a 12-month trial found no effect on objective nerve measures, and a 24-month trial in type 1 diabetes found none either.

What dose of benfotiamine should I take for nerve health?

Trials used 300 to 600 mg per day. The BENDIP trial compared both doses head to head and found the 600 mg dose worked better, with the effect growing over the six weeks. A sensible approach is 300 mg daily for the first month, then 600 mg if you tolerate it well and want to match the stronger trial arm.

Is benfotiamine better than regular vitamin B1?

For absorption, yes, and that part is well proven. Ordinary thiamine hits an absorption ceiling of roughly 8 to 15 mg per day, while benfotiamine slips past it; one pharmacokinetic study measured about 11 times more thiamine reaching the bloodstream. Whether that translates into better nerve outcomes than cheap B1 has never been tested head to head in a neuropathy trial.

How long does benfotiamine take to work?

The BEDIP pilot detected improvement at three weeks, and the BENDIP trial found the effect grew between week three and week six. Give it six to twelve weeks at 300 to 600 mg daily while tracking your tingling and burning on a 0-to-10 scale. If nothing changes by week twelve, the long trials suggest it is unlikely to change later.

Can I take benfotiamine with alpha-lipoic acid?

No interaction between the two is known, and European nerve formulas have combined B vitamins with alpha-lipoic acid for years. The practical rules from the trials still apply: introduce one at a time, watch your blood sugar if you use insulin or sulfonylureas, and treat the combination as an add-on to glucose control, never a substitute for it.

Editorial standards. Our team reviews published studies and official fact sheets before any guide goes live. We do not sell supplements. Content is not reviewed by a licensed physician. Health after 50, in plain English.
Medical disclaimer. After 50 Strong publishes general information, not medical advice. Talk to your doctor before starting any supplement, especially if you take prescription medication. Full text: medical disclaimer.
Contact. Questions, corrections or product tips: email [email protected] or use the contact page. We answer within 48 hours.
Scroll to Top